Structured evidence table for Coenzyme Q10 Energy Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Coenzyme Q10 Energy Randomized Trial | Despite major advancements in pharmacotherapies and interventional cardiology, substantial residual risk persists among patients with established disease (). | 3 | Wu Xun (2026) | Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives |
| Coenzyme Q10 Energy Randomized Trial | Additionally, many nutraceuticals are perceived to possess favorable safety and tolerability profiles compared to conventional medications, making them attractive for long-term risk reduction (). | 3 | Wu Xun (2026) | Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives |
| Coenzyme Q10 Energy Randomized Trial | Banach et al., 2018 Cicero et al., 2017 Sesso et al., 2008 However, the field is marked by heterogeneous and sometimes contradictory evidence. | 3 | Wu Xun (2026) | Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives |
| Coenzyme Q10 Energy Randomized Trial | Roth et al., 2020 Ganda et al., 2018 Visseren et al., 2021 Cardiovascular disease (CVD) is the leading cause of mortality worldwide, accounting for nearly one-third of global deaths each year (). | 3 | Wu Xun (2026) | Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives |
| Coenzyme Q10 Energy Randomized Trial | 1 2 1 1 3 4 Nutrients Advances in Nutrition for MASLD Management: Current Perspectives from the Bench to the Bedside Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), has emerged as the most prevalent chronic liver disease worldwide, with an overall global prevalence of 30% [,]. | 4 | Rodriguez-Ramiro Ildefonso (2026) | Advances in Nutrition for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management: Current Perspectives from the Bench to the Bedside |
| Coenzyme Q10 Energy Randomized Trial | It encompasses from hepatic steatosis, through to metabolic dysfunction-associated steatohepatitis (MASH), the progressive necroinflammatory disease form that can progress to fibrosis, cirrhosis, and hepatocellular carcinoma []. | 4 | Rodriguez-Ramiro Ildefonso (2026) | Advances in Nutrition for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management: Current Perspectives from the Bench to the Bedside |
| Coenzyme Q10 Energy Randomized Trial | It is recognized as a complex systemic metabolic disorder closely linked to obesity, insulin resistance, cardiometabolic dysfunction, gut microbial dysbiosis, and genetic risk factors []. | 4 | Rodriguez-Ramiro Ildefonso (2026) | Advances in Nutrition for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Management: Current Perspectives from the Bench to the Bedside |
Source documents